– This year, sales volume has increased by 40% compared to the previous year with exceeding 300 vials in April.

On April 20, MEDIPOST announced that the domestic market expansion of arthritis for stem cell therapy, ‘CARTISTEM^®’, is beginning to take effect.

Prescriptions in Korea for ‘CARTISTEM^®’ have hit records of 1,100 vials already this year, and this is a figure that has increased by more than 40% in comparison to last year.

In particular, CARTISTEM^® has passed 300 vials in the single month of April, which is the first time that the monthly sales of CARTISTEM^® has passed such a figure.

Last year, CARTISTEM^®‘s first domestic sales of stem cell therapy exceeded 10 billion won in sales, thereby becoming a blockbuster drug.

Taking into account such growth, MEDIPOST forecasts that the cumulative sales of “CARTISTEM^®” will exceed 10,000 vials by the end of this year.

Regarding this, the MEDIPOST representative explained that “the recent market for osteoarthritis (OA) treatment with biopharmaceutical products is growing as a whole,” and that since its introduction to the market in 2012, ‘CARTISTEM^®’ is continuously increasing in sales volume and such a trend is expected to continue.”

“CARTISTEM^®” is the Treatment of the repetitive and/or traumatic cartilage degeneration including degenerative Osteoarthritis (OA)) and the drug substance is based on Allogenic Umbilical Cord Blood Derived Mesenchymal Stem Cells.